Etrasimod

Drug Profile

Etrasimod

Alternative Names: APD 334

Latest Information Update: 23 Mar 2017

Price : $50

At a glance

  • Originator Arena Pharmaceuticals
  • Class Antirheumatics; Small molecules
  • Mechanism of Action Sphingosine 1 phosphate receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Inflammatory bowel diseases; Pyoderma; Ulcerative colitis

Most Recent Events

  • 14 Mar 2017 Arena Pharmaceuticals plans a phase II trial for Primary biliary cholangitis
  • 10 Mar 2017 Arena Pharmaceutical plans a phase II trial for Pyoderma gangrenosum (NCT03072953)
  • 30 Mar 2016 Arena Pharmaceuticals has patent protection for APD 334 in USA, Japan, China, Australia and Russia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top